Compare Stocks: TCRT, BCLI, BLRX, and PHIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$0.95 +3.3%	$0.98	$0.46 ▼ $1.69	$13.55M	0.28	20,211 shs	8,736 shs
BLRX BioLineRx	$2.33 -0.9%	$2.67	$2.15 ▼ $4.56	$11.30M	1.56	28,057 shs	6,343 shs
PHIO Phio Pharmaceuticals	$1.02 -1.0%	$1.07	$0.81 ▼ $4.19	$11.85M	0.8	1.50 million shs	41,557 shs
TCRT Alaunos Therapeutics	$0.92 +3.2%	$1.65	$0.85 ▼ $4.59	$2.33M	-0.97	280,228 shs	26,950 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	+3.26%	+9.18%	-10.80%	-34.03%	+34.26%
BLRX BioLineRx	-0.25%	-8.20%	-16.07%	-28.57%	-37.83%
PHIO Phio Pharmaceuticals	0.00%	+0.98%	-5.50%	+3.00%	-58.47%
TCRT Alaunos Therapeutics	-7.60%	-22.83%	-47.79%	-57.33%	-63.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$0.95 +3.3%	$0.98	$0.46 ▼ $1.69	$13.55M	0.28	20,211 shs	8,736 shs
BLRX BioLineRx	$2.33 -0.9%	$2.67	$2.15 ▼ $4.56	$11.30M	1.56	28,057 shs	6,343 shs
PHIO Phio Pharmaceuticals	$1.02 -1.0%	$1.07	$0.81 ▼ $4.19	$11.85M	0.8	1.50 million shs	41,557 shs
TCRT Alaunos Therapeutics	$0.92 +3.2%	$1.65	$0.85 ▼ $4.59	$2.33M	-0.97	280,228 shs	26,950 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	+3.26%	+9.18%	-10.80%	-34.03%	+34.26%
BLRX BioLineRx	-0.25%	-8.20%	-16.07%	-28.57%	-37.83%
PHIO Phio Pharmaceuticals	0.00%	+0.98%	-5.50%	+3.00%	-58.47%
TCRT Alaunos Therapeutics	-7.60%	-22.83%	-47.79%	-57.33%	-63.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	0.00	N/A	N/A	N/A
BLRX BioLineRx	1.00	Sell	N/A	N/A
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,272.55% Upside
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRT, BCLI, BLRX, and PHIO Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/26/2026	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
BLRX BioLineRx	$1.18M	9.58	N/A	N/A	$5.36 per share	0.43
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$1.65	N/A	N/A	N/A	N/A	N/A	-519.50%	11/16/2026 (Estimated)
BLRX BioLineRx	-$1.17M	-$1.69	N/A	N/A	N/A	-502.08%	-34.80%	-18.27%	11/23/2026 (Estimated)
PHIO Phio Pharmaceuticals	-$8.70M	-$1.29	N/A	N/A	N/A	N/A	-87.41%	-79.76%	11/12/2026 (Estimated)
TCRT Alaunos Therapeutics	-$4.18M	-$1.91	N/A	N/A	N/A	N/A	-232.60%	-158.99%	11/17/2026 (Estimated)

Latest TCRT, BCLI, BLRX, and PHIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q2 2026	BLRX BioLineRx	-$0.15	-$0.77	-$0.62	N/A	$0.50 million	$0.29 million
8/14/2026	Q2 2026	BCLI Brainstorm Cell Therapeutics	-$0.29	-$0.35	-$0.06	N/A	N/A	N/A
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
BLRX BioLineRx	0.13	1.20	1.04
PHIO Phio Pharmaceuticals	N/A	8.39	8.39
TCRT Alaunos Therapeutics	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
BLRX BioLineRx	1.56%
PHIO Phio Pharmaceuticals	57.31%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
BLRX BioLineRx	1.10%
PHIO Phio Pharmaceuticals	3.52%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	14.26 million	8.74 million	Optionable
BLRX BioLineRx	24	4.85 million	4.80 million	Optionable
PHIO Phio Pharmaceuticals	6	11.62 million	11.21 million	Not Optionable
TCRT Alaunos Therapeutics	1	2.54 million	2.13 million	No Data

TCRT, BCLI, BLRX, and PHIO Headlines

Recent News About These Companies

Alaunos Therapeutics Announces New Registered Direct Offering

September 22, 2026 | tipranks.com

Alaunos Prices $1.12M Registered Direct Offering

September 19, 2026 | rttnews.com

Alaunos Therapeutics Stock Falls 17% After Public Offering Announcement

September 19, 2026 | rttnews.com

Alaunos Therapeutics prices direct offering at $1.46 per share

September 19, 2026 | streetinsider.com

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

September 18, 2026 | globenewswire.com

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

September 18, 2026 | benzinga.com

Alaunos Therapeutics Updates Bylaws to Ease Shareholder Quorum

September 17, 2026 | tipranks.com

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, BCLI, BLRX, and PHIO Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.95 +0.03 (+3.26%)

As of 12:32 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BioLineRx NASDAQ:BLRX

$2.33 -0.02 (-0.85%)

As of 02:07 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Phio Pharmaceuticals NASDAQ:PHIO

$1.02 -0.01 (-0.97%)

As of 02:15 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Alaunos Therapeutics NASDAQ:TCRT

$0.92 +0.03 (+3.21%)

As of 02:17 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, BCLI, BLRX, and PHIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, BCLI, BLRX, and PHIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, BCLI, BLRX, and PHIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, BCLI, BLRX, and PHIO Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

BioLineRx NASDAQ:BLRX

Phio Pharmaceuticals NASDAQ:PHIO

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRT, BCLI, BLRX, and PHIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRT, BCLI, BLRX, and PHIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRT, BCLI, BLRX, and PHIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, BCLI, BLRX, and PHIO Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

BioLineRx NASDAQ:BLRX

Phio Pharmaceuticals NASDAQ:PHIO

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools